Search research articles
Contact Us
Filters
Showing results (671-680 of 724) with videos related to
Page
of 73
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2015
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials
Y Sunakawa, S Stintzing, S Cao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 15, 2017
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)
Roger von Moos, Dieter Koeberle, Sabina Schacher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 20, 2020
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials
Martin D Berger, Yan Ning, Sebastian Stintzing, et al.
International Journal of Cancer
|
June 2, 2017
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer
Satoshi Okazaki, Sebastian Stintzing, Yu Sunakawa, et al.
Clinical Colorectal Cancer
|
April 3, 2018
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib
Mitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
The Pharmacogenomics Journal
|
June 1, 2016
Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer
Y Sunakawa, S Cao, N B Volz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2017
A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab
Martin D Berger, Sebastian Stintzing, Volker Heinemann, et al.
JAMA
|
April 2, 2024
Pulmonary Vein Isolation With or Without Left Atrial Appendage Ligation in Atrial Fibrillation: The aMAZE Randomized Clinical Trial
Dhanunjaya R Lakkireddy, David J Wilber, Suneet Mittal, et al.
Clinical Epigenetics
|
September 28, 2018
CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway
Janina Graule, Kristin Uth, Elia Fischer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 29, 2017
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials
Martin D Berger, Shinichi Yamauchi, Shu Cao, et al.
Page
of 73
Search research articles
Search
Showing results (671-680 of 724) with videos related to
Sort By:
Page
of 73
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2015
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials
Y Sunakawa, S Stintzing, S Cao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 15, 2017
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)
Roger von Moos, Dieter Koeberle, Sabina Schacher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 20, 2020
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials
Martin D Berger, Yan Ning, Sebastian Stintzing, et al.
International Journal of Cancer
|
June 2, 2017
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer
Satoshi Okazaki, Sebastian Stintzing, Yu Sunakawa, et al.
Clinical Colorectal Cancer
|
April 3, 2018
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib
Mitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
The Pharmacogenomics Journal
|
June 1, 2016
Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer
Y Sunakawa, S Cao, N B Volz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2017
A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab
Martin D Berger, Sebastian Stintzing, Volker Heinemann, et al.
JAMA
|
April 2, 2024
Pulmonary Vein Isolation With or Without Left Atrial Appendage Ligation in Atrial Fibrillation: The aMAZE Randomized Clinical Trial
Dhanunjaya R Lakkireddy, David J Wilber, Suneet Mittal, et al.
Clinical Epigenetics
|
September 28, 2018
CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway
Janina Graule, Kristin Uth, Elia Fischer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 29, 2017
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials
Martin D Berger, Shinichi Yamauchi, Shu Cao, et al.
Page
of 73